NCT05850416 mGlide-Care: A Partnership With Caregivers
| NCT ID | NCT05850416 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | HTN |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2028-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2026-01-15 with a primary completion date of 2028-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypertension (HTN) is the most significant stroke, cardiovascular disease and dementia risk factor and is substantially under-treated especially in older persons. In this study the investigators will develop mGlide-Care to address uncontrolled HTN in people with mild cognitive impairment (MCI) and early stage Alzheimer's Disease and Alzheimer's Disease Related Dementia (AD/ADRD). mGlide-Care is adapted from mGlide which is a mHealth (mobile health technology) mediated care model for HTN care. Aim 1 will engage stakeholders to study the acceptability of mHealth mediated HTN care and will use their input to develop mGlide-Care. Stakeholders are persons with early stage AD/ADRD and MCI, unpaid family caregivers, primary care providers, geriatricians and clinical pharmacists. Aim 2 is a feasibility pilot to test mGlide-Care vs. usual care in 75 participants with uncontrolled HTN and early stage AD/ADRD or MCI. Caregivers will assist participants. Outcomes will include HTN control and participant and caregiver reported measures.
Eligibility Criteria
Inclusion Criteria: Must meet all criteria * Diagnosed with early stage AD/ADRD or MCI * Have uncontrolled hypertension (HTN) * Have an unpaid, family caregiver * Have established medical diagnosis of hypertension (HTN) * English speaking * Participant or caregiver must have a smartphone or mobile device (e.g. iPad) that can transmit blood pressure (BP) from the BP monitor * Participant and caregiver capable and willing to comply with the entire study protocol * Able to give voluntary written informed consent. Exclusion Criteria: Any of the following will be an exclusion. * Severe comorbid illness including end-stage kidney disease, end-stage liver disease, and life expectancy \<1 year, or if medical complexity of the patient precludes clinical trial participation * Active illicit drug use (e.g. cocaine, methamphetamines, opioids, phencyclidine) since this will interfere with HTN management * Participant and caregiver unable to complete study tasks, including are homeless, will leave the country, or will relocate in the next 12 months * Serious psychiatric illness that could interfere with treatment, assessment, or compliance including significant delusional disorders such as schizophrenia and bipolar illness * Unable or unwilling to give consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05850416 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 85 Years, studying HTN. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05850416 currently recruiting?
Yes, NCT05850416 is actively recruiting participants. Contact the research team at mGlideCare@umn.edu for enrollment information.
Where is the NCT05850416 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT05850416 clinical trial?
NCT05850416 is sponsored by University of Minnesota. The trial plans to enroll 75 participants.